# Multi-Omics Meets Premalignancy: Paving the Way for Early Prevention of Cancer

**Authors:** Feiran Zhang, Ziyi Zhou, Peng Zhang, Shao Li

PMC · DOI: 10.34133/research.0930 · Research · 2025-10-17

## TL;DR

This paper explores how combining multi-omics data and AI can improve early cancer detection and prevention by studying premalignant lesions.

## Contribution

The paper introduces a comprehensive catalog of premalignant lesions across 15 cancer types and discusses novel AI-driven strategies for early cancer interception.

## Key findings

- Multi-omics and AI reveal dynamic molecular and cellular changes in premalignant to cancerous transitions.
- Network-based strategies and deep learning enhance understanding of tumorigenesis trajectories.
- High-precision biomarkers and preventive strategies are feasible through integrated omics and AI.

## Abstract

Comprehensive understanding of premalignant lesions (PMLs) represents a pivotal opportunity for cancer early detection and interception. Recently, advances in multi-omics technologies and artificial intelligence (AI) methods have provided unprecedented insights into PML-induced tumorigenesis. In this paper, we firstly catalog clinically recognized PMLs across 15 cancer types, emphasizing their epidemiological profiles and malignant transformation potentials. Then, we summarize recent intriguing discoveries and remaining challenges from bulk, single-cell, and spatial omics studies, highlighting how these omics technologies reveal the dynamic molecular, cellular, and spatial evolution from precancerous states to invasive malignancies. We further discuss network-based computational strategies for multi-omics integration and tumorigenesis trajectory inference, with applications of recent deep learning-based AI approaches. Finally, we highlight translational implications for PMLs, including developing high-precision early-diagnosis biomarkers and targeted pharmacological preventive strategies. Collectively, this paper underscores how the convergence of high-resolution multi-omics with sophisticated AI is poised to redefine PML research, enabling pan-cancer exceedingly-early risk stratification and pharmacological prevention.

## Full-text entities

- **Genes:** PML (PML nuclear body scaffold) [NCBI Gene 5371] {aka MYL, PP8675, RNF71, TRIM19}
- **Diseases:** Cancer (MESH:D009369), PMLs (MESH:D009059), tumorigenesis (MESH:D063646)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12620627/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12620627/full.md

## References

195 references — full list in the complete paper: https://tomesphere.com/paper/PMC12620627/full.md

---
Source: https://tomesphere.com/paper/PMC12620627